Diabetes Project Update (14 Aug 2009)

Compound:
Phenyl propionic acid derivative No 3

Company Name:
Adamed Sp. z o.o. (Private)

Product Name:
Compound no 3

Indication:
Diabetes Type 2

Drug Class:
Diabetes (A10)

Trial Phase:
IND/Phase I

Route of Administration:
Oral

Mechanism of Action:
Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-Gamma) Partial Agonist

Mode of Action:
Hypoglycemic; Insulin Sensitizer

Milestones:
The company expects to initiate Phase I in January 2010.

Description:
Compound no 3 is an orally administered active small molecule drug candidate that is a partial agonist of PPAR gamma (peroxisome proliferator activated receptor gamma), a transcription factor involved in regulating of genes controlling carbohydrates and lipids metabolism, as well as insulin response to food intake. Compound no 3 is phenyl propionic acid derivative and is not structurally related to the thiazolidinedione (TZD) group of PPAR gamma agonists.

Read more...
INSIDE - Cenne jest to, co w środku

Najnowszym osiągnięciem laboratoriów Adamed jest stworzenie marki
Inside, która pozwala przenieść nasze doświadczenie z rynku medycznego w świat dermokosmetyków....
Diabetes Project Update (14 Aug 2009)

Compound:
Phenyl propionic acid derivative No 3

Company Name:
Adamed Sp. z o.o. (Private)

Product Name:
Compound no 3

Indication:
Diabetes Type 2
(more details)...